Pharmaceutical

bit.bio defends European patent for ‘novel’ opti-ox technology

bit.bio’s method for pluripotent stem cell (PSC) programming, opti-ox, was deemed sufficiently novel and inventive.

Oct 18, 2024 - 04:00
bit.bio defends European patent for ‘novel’ opti-ox technology
bit.bio’s method for pluripotent stem cell (PSC) programming, opti-ox, was deemed sufficiently novel and inventive.
Read the original article

Tags:

Previous Article

Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to gover...

Next Article

Radiopharm and AtomVie partner on radioantibody development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Drug shortages and the supply chain are a matter of national security, experts say

STAT+: Drug shortages and the supply chain are a matter...

Nov 7, 2023

STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit

STAT+: A Q&A with the global head of Boehringer Ingelhe...

Oct 10, 2023

STAT+: Federal advisory group rejects proposal to make medical device tracking easier

STAT+: Federal advisory group rejects proposal to make ...

Jun 14, 2023